drugset / Trial / NCT07649525
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
Phase 3
Recruiting
1226 enrolled
University of Leeds
Blood Cancer UK · collabCancer Research UK · collabJohnson & Johnson · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
iFIT is a trial for newly diagnosed transplant-ineligible patients with the bone marrow cancer myeloma. These patients are generally older and have a lower level of fitness than others. Patients can take part if their doctor would otherwise recommend the standard NHS treatment daratumumab, lenalidomide and dexamethasone (DRd). After six months of DRd, the subsequent treatment a patient receives in iFIT is based on two factors: the patient's fitness level and treatment response. The trial compares different treatment strategies to determine whether outcomes can be improved for specific patient groups.
Timeline
- Start
- 2026-07
- Primary completion
- 2033-06
- Completion
- 2037-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daratumumab | Monoclonal antibody | — | Subcutaneous |
| Comparator | Dexamethasone | Small molecule | — | Oral |
| Subject | Lenalidomide | Other / unclassified | — | Oral |
| Subject | Talquetamab | Monoclonal antibody | — | Subcutaneous |
| Subject | Teclistamab | Monoclonal antibody | — | Subcutaneous |